Skip to main content

Table 1 Patient characteristics and data for each patient

From: Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration

Patient no, Sex, Age (yrs)

CNV Type

Pretreatment BCVA (LogMAR)

24- week BCVA (LogMAR)

No of Retreatments

Follow-up (weeks)

1, M, 75

Occult

0.60

0.60

2

61

2, F, 64

Occult

0.90

0.90

0

73

3, M, 65

Minimally classic

0.78

0.48

0

46

4, F, 54

Occult

0.48

0.00

0

24

5, M, 65

Occult

1.20

0.10

2

68

6, F, 55

Classic

0.78

0.48

2

58

7, M, 67

Classic

0.30

0.00

1

56

8, F, 60

Classic

0.78

0.00

2

59

9, F, 68

RAP

0.60

0.10

2

57

10, M, 70

Occult

0.30

0.10

3

65

11, F, 75

Occult

0.60

0.40

0

52

12, F, 74

Classic

1.20

0.40

0

25

13, M, 73

Classic

0.48

0.30

3

52

14, F, 82

Minimally classic

1.20

1.20

1

57

15, F, 67

Minimally classic

0.22

0.15

1

26

16, F, 65

Occult

1.00

1.00

0

48

17, M, 71

Occult

1.10

0.78

0

30

Mean BCVA (Snellen) ± SD

 

0.74 (20/100) ± 0.33

0.41 (20/50) ± 0.38